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Editorial on the Research Topic
The Role of Breast Cancer Stem Cells in Clinical Outcomes
Breast cancer stem cells (BCSCs) or tumor-initiating cells (TICs) constitute a small, dynamic
subpopulation of breast tumors and are important drivers of tumor initiation, progression and
metastasis [Sridharan, Howard et al., (1, 2)]. They play a vital role in constitutive or acquired drug
resistance or chemoresistance that results in poor patient outcomes (3). Following conventional
cytotoxic or radiotherapy, the inherently resistant and surviving BCSCs, non-BCSC tumor and
stromal cells constitute the minimal residual disease (MRD) (3, 4). Subsequently, these BCSCs
expand and undergo multilineage differentiation and repopulate the heterogeneous tumor. The
relapsed tumor is highly aggressive, probably cross-drug resistant and highly metastatic, posing
grave prognosis. BCSCs possess innate or develop acquired chemoresistance as they have the ability
to detoxify or transport out the chemotherapeutic drug through a variety of mechanisms. This
directs our focus to either selectively target BCSCs or co-target BCSCs and non-BCSCs (bulk
tumor cells) to overcome chemoresistance and achieve clinical success in metastatic breast cancer
(MBC) patients. Vulnerable targets or signaling nodes should be identified and targeted in BCSCs.
Importantly, the biological characteristics, molecular pathways that sustain stemness, induction
of resistance mechanisms, facilitation of the plasticity of the BCSCs should be ascertained (5).
Mathematical modeling approaches may be employed to discern the behavior of the BCSCs and
its niche (6, 7). Additionally, nanotechnology and targeted delivery of drugs must be developed
and tailored to improve the drug efficacy and minimize the adverse events in the patients.
In this special guest edition, Zhou et al., have elegantly reviewed cellular origins of the
breast cancer to understand heterogeneity, a variety of BCSC markers, regulatory signaling
pathways, microRNAs and therapeutic strategies in different subtypes of BC. BCSCs also
rewire their energetics to bolster their survival (8). Energetic CSCs are a subset of BCSCs
that demonstrate increased proliferative capacity, enhanced anchorage-independent growth and
aldehyde dehydrogenase positivity (9, 10). Walsh et al., have reviewed the various factors that
enable the BCSCs to flick the energetic switch to gain metabolic plasticity. Targeting such metabolic
vulnerabilities would be a powerful approach to combat BC stemness. Redox processes also play
a vital role in the viability of BCSCs to detoxify xenobiotics and control the level of reactive
oxygen species. Recent evidence suggests that by targeting the redox status, the mesenchymal
state of BCSCs can be switched to epithelial type which is comparatively more susceptible to
cytotoxic drugs (11). BCSCs also evade the immune system but they are strongly antigenic as per
Khandekar et al., enabling naïve CD8+ effector T-cells to eliminate BCSCs. The challenge would
be in a situation where CD8+ T-cells are anergic or rendered quiescent through the engagement
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of their programmed death receptor-1 (PD-1) with the PD1
ligand (PD-L1) Khandekar et al. Empowering the CD8+ T-
cells with anti PD-1 or anti-PD-L1 immunotherapy would
synergize with BCSC-directed therapy. Sridharan, Howard et al.
have comprehensively reviewed various molecular targets in
BCSCs that would render them susceptible for targeted therapy.
In particular, targeting various molecular signaling receptors
and downstream mediators that would reduce stemness and
overcome chemoresistance of BCSCs were described. Sridharan,
Robeson et al. have discovered a key vulnerability in BCSCs in
that they are dependent on certain pro-survival factors such as
survivin and Myeloid Cell Leukemia 1(MCL1) for their distinct
survival advantages. Both survivin and MCL1 are also involved
in chemoresistance (12). Also, oncotargets such as cyclin D1 and
cyclin D3 are also key for BCSCs to maintain their clonogenicity.
Interestingly, all these targets have one thing in common; the
5′-leader sequence of their mRNAs has a classical secondary
structure that hinders facile mRNA translation by the ribosome.
This problem can be rectified by the mRNA helicase eIF4A
(13). By targeting this single enzyme eIF4A, the translation
of a whole set of oncogenic mRNAs such as survivin, MCL1,
cyclin D1, cyclin D3, mucin-1C, Rho kinase 1, STAT1 (this
controls PD-L1 transcript level), and MDM2/HDM2 (controls
wild type p53 level) will be obliterated (14). Importantly, the
pluripotency transcription factors OCT4, SOX2 and NANOG
were significantly downregulated when eIF4A was genetically
ablated or pharmacologically targeted. This is the first report that
targeting of eIF4A could downregulate BC stemness Sridharan,
Robeson et al. Furthermore, the levels of ATP-binding cassette
(ABC) transporters that export the xenobiotics were significantly
reduced. This brings an important point in that targeting
eIF4A not only controls BC stemness but also can overcome
chemoresistance through downregulation of drug transporters
Sridharan, Robeson et al. Importantly, eIF4A is distributed
equally between BCSCs and non-BCSCs and so both cellular
populations will be killed simultaneously leaving little chance
for MRD, relapse and aggressive tumor. eIF4A is a promising
new target in BCSCs and targeting eIF4A may help improve
the clinical outcome. There is an ongoing clinical trial targeting
eIF4A by eFT226 by Effector Therapeutics (NCT04092673) and
hopefully beneficial for advanced cases of breast cancer.
As BCSCs play a role in drug tolerance and resistance,
targeting the plasticity may lead to a profound and more
durable response. A combinatorial treatment approach may
overcome the multidrug resistance (MDR) encountered in the
clinic. During cytotoxic and targeted therapies, activation of
phosphatidylinositol-3-kinase (PI3K), yes-associated protein
(YAP) signaling, up regulation of anti-apoptotic MCL1,
hepatocyte growth factor [HGF; secreted by the carcinoma
associated fibroblasts (CAFs)], insulin-like growth factor
receptor (IGFR), epidermal growth factor (EGF) receptor and
AXL ligand are frequently observed leading to chemoresistance
(15). Tumors (primary or metastatic) enriched in CAFs (tumor
microenvironment—TME) is likely to secrete HGF (ligand
for c-Met receptor), CXCL12 (ligand for chemokine receptor
CXCR4), and these factors may contribute to chemoresistance.
Importantly, the difference in the TME between primary and the
metastatic lesions should be considered as it may also dictate
and produce diverse clinical outcomes. Based on biopsy results
of such lesions, the level of PD-L1, PD-1 may also be assessed
and appropriate co-targeted therapy directed toward cellular
TME, BCSCs, and non-BCSCs should be devised. Combined
targeting of these pathways along with a known targeted therapy
may produce a better objective treatment response in containing
BCSC and non-BCSC cell populations.
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